MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon Purchases 143,170 Shares

MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon bought 143,170 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was bought at an average price of $10.84 per share, for a total transaction of $1,551,962.80. Following the completion of the purchase, the director now directly owns 3,255,000 shares of the company’s stock, valued at $35,284,200. The trade was a 4.60 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

MBX Biosciences Price Performance

MBX Biosciences stock opened at $11.22 on Thursday. MBX Biosciences, Inc. has a one year low of $8.63 and a one year high of $27.50. The business’s 50-day moving average price is $14.22.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MBX. BNP Paribas Financial Markets bought a new stake in shares of MBX Biosciences during the fourth quarter valued at approximately $27,000. Virtus ETF Advisers LLC acquired a new stake in MBX Biosciences in the 4th quarter valued at approximately $64,000. The Manufacturers Life Insurance Company raised its stake in MBX Biosciences by 7.5% during the 4th quarter. The Manufacturers Life Insurance Company now owns 49,675 shares of the company’s stock valued at $916,000 after acquiring an additional 3,481 shares in the last quarter. Deutsche Bank AG acquired a new position in MBX Biosciences during the 4th quarter worth $80,000. Finally, Corebridge Financial Inc. bought a new position in shares of MBX Biosciences in the fourth quarter worth $103,000.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.